Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
Open Access
- 9 June 2006
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (8), 1296-1300
- https://doi.org/10.1093/annonc/mdl122
Abstract
Background: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients. Patients and Methods: Between June 2003–September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles. All these patients underwent staging/restaging: computed tomography (CT) and positron emission tomography (PET) at time 0, PET after two cycles, CT and PET after four and six cycles. Results: After two cycles (PET-2), the PET was negative in 28/40 (70%), positive in 8/40 (20%), and minimal residual uptake (MRU) was present in the remaining four (10%) patients. After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months. All four patients with MRU at the PET-2 became PET_ during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months. All 28 PET negative patients at the PET-2 remained PET negative and all of them were in CR after treatment. Conclusions: The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.Keywords
This publication has 20 references indexed in Scilit:
- The clinical value of tumor burden at diagnosis in Hodgkin lymphomaCancer, 2004
- Predictive role of positron emission tomography (PET) in the outcome of lymphoma patientsBritish Journal of Cancer, 2004
- FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients withde novoHodgkin Lymphoma: A Blinded ComparisonLeukemia & Lymphoma, 2004
- [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction?European Journal of Nuclear Medicine and Molecular Imaging, 2003
- Advantages of Positron Emission Tomography (PET) with Respect to Computed Tomography in the Follow-up of Lymphoma Patients with Abdominal PresentationLeukemia & Lymphoma, 2002
- Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphomaBritish Journal of Haematology, 2001
- Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin diseaseBlood, 2001
- A pilot study to assess the feasibility of prior scalp cooling with palliative whole brain radiotherapy.The British Journal of Radiology, 2000
- The role of positron emission tomography (PET) in the management of lymphoma patientsAnnals of Oncology, 1999
- Positron Emission Tomography (PET) for Staging and Evaluation of Response to Treatment in Patients with Hodgkin's DiseaseLeukemia & Lymphoma, 1999